Abstract -In order to establish a noninvasive cancer therapy with minimal side effects, low cost, and specific in targeting tumor cells. The team engineered novel and biocompatible Upconversion Nanoparticles (UCNPs) with a calcium fluoride shell α-NaYF4:Yb,Er@CaF2 and conjugated with an FDA approved prodrug 5-Aminolevulinic Acid (ALA). In conjunction with photodynamic therapy (PDT), deep tissue penetration was achieved. UCNPs convert near-infrared light into visible light when excited at ~980nm. Emission of the red light from the UCNPs activate the photosensitizer protoporphyrin (PpIX), causing the production of reactive oxygen species (ROS) causing the death of targeted tumor.
I. INTRODUCTION
Cancer is an uncontrolled growth of cells in human body. It is the second cause of death in the US, with 1,660,290 new expected cases and about 580,350 expected to die in 2013 [1] . Cancer has a variety of treatments, and the most popular ones are chemotherapy, radiotherapy and surgery, but all of these treatments are not ideal in every cancer case especially in the later stages where metastasis occurs. Due to the side effects that cancer treatments have, scientists are always looking to improve current treatments and find better alternatives [2] .
Photodynamic therapy (PDT) with Upconversion nanoparticles (UCNPs) is a treatment that shows significant potential in this field. PDT is a treatment that uses a photosensitizing agent. When photosensitizers are exposed to a visible UV wavelength of light, they produce singlet oxygen (1O2) that kills nearby cells; it has been used mostly for skin diseases [3] . UCNPs, is a mixture of lanthanide-doped Nanocrystals, which emit high-energy photons and visible UV light under excitation by the near-infrared (NIR) light. Using both PDT and UCNPs for cancer treatment showed promising results especially in In-vivo testing [4] .
The nanoparticles that have been used with photodynamic therapy for cancer treatment are being excited at 980nm wavelength, which showed good results [5] . Ytterbium (Yb 3+ ) sensitizer, which is the element commonly used for its unalterable excitation band centered at 980nm. Also, a longer wavelength from the UCNP with NIR makes the exciting light into biological tissue with deeper penetration.
Along with the UCNP, 5-aminolevulinic acid (ALA) is also currently used clinical PDT. Through the heme biosynthesis, ALA, which has a hydrophilic characteristic and selectivity for PpIX production in cancer cells, triggers and generates the red-absorbing photosensitizer protoporphyrin IX (PpIX). Due to the team's project goal of targeting cancer cells, ALA was suitable application to the designed UCNP. Nevertheless, ALA disperses red light for the usage within the accessible places by an endoscope such as tumors on the skin like other photosensitizer's applications. Furthermore, ALA usage in PDT requires to have red emitted light converted from NIR light in order to activate PpIX.
Therefore, the aim of this project is to use of photodynamic therapy with nanoparticles by designing UCNPs which will enhance the level of red emission at 980nm wavelength. We had reproduced Yb 3+ and Tm UCNPs with blue light emission to learn the techniques [6] , and the skills that are needed to create UCNPs, then started producing Calcium Fluoride (CaF 2 ) shell with Yb 3+ as final design product by comparing the elements that been used to create UCNPs and its chemical properties. With the CaF 2 UCNPs, we proceeded into few sets of experiments to verify which design satisfies requirements. Transmission Electron Microscopic (TEM) images were obtained in order to check the CaF 2 particle sizes and uniformity, then emission spectra data was acquired to check its quantitative values of its emission brightness.
After we had established that α-NaYF 4 :Yb,Er@CaF 2 has been proved the red emission shown in Figure 1 for the further experiments with ALA synthesis, it was conjugated with the ALA via hydrazone linkage. Once the ALA-UCNPs phagocytosed by cells, the linkage was then broken when exposed to an acidic environment in the endosome. The ALA diffuses out of the endosome to the mitochondria and disrupts the heme biosynthesis causing the overproduction of the PpIX. Where then the UCNPs left in the cytoplasm activate the PpIX, after the exposure to NIR light causing the death of targeted tumor.
As a verification process, Fourier Transform Infrared Spectroscopy (FTIR) and High-performance liquid chromatography (HPLC) were performed to check the completion of ALA-synthesis. In addition, Microculture Tetrazolium (MTT) cell proferation Assay was also performed to verify its toxicity within the biological organisms. Along with its toxicity testing, Cellular Reactive Oxygen Species Detection Assay (DCFDA) was performed to measure the singlet oxygen production. In addition, Figure 3 below shows TEM images of the uniform distribution of ALA-UCNPs in water and hydrodynamic size is about 62 nm. As part of the result, FTIR spectral analysis for PAAUCNPs the peaks at 1550cm -1 and 1408cm -1 correspond to the -N-H-bending and stretching vibration of NH + respectively.
Finally the ALA-UCNP spectrum displays two new peaks at 1628cm -1 and 1550cm -1 resembling the -N=N-bond between the hydrazine-functionalized UCNPs-ALA and the acidicsensitive covalent linkage fabricated established between the ALA and the UCNPs. Additionally, HPLC analysis determined the loading capacity of the ALA is 48 µmol/10mg on the UCNPs, which is appropriate to induce PpIX production in cells at a 100 µg/mL concentration. MTT assay conducted using different controls in which hela cells exposed and followed by irradiation of CW 980nm light at 1 W/cm2. The team's result showed a sever decrease in cell viability after 10min of exposure to the ALA-UCNPs, where only 30% cell survival occurs. Following with the toxicity assay, the production of ROS was determined using DCFDA staining, where cells exposed to ALA-UCNPs revealed significant increase in the DCFDA fluorescence intensity. Quantitative data collected using 96 well-plate also measuring the fluorescence intensity of the DCFDA.
